Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa M Lavange

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Statistics in Biopharmaceutical Research|June 30, 2021
Statistical Challenges in the Conduct and Management of Ongoing Clinical Trials During the COVID-19 PandemicToshimitsu Hamasaki, Frank Bretz, Freda Cooner, et al.
Journal of the American Statistical Association|May 3, 2014
Power Calculations for General Linear Multivariate Models Including Repeated Measures ApplicationsKeith E Muller, Lisa M Lavange, Sharon Landesman Ramey, et al.
JAMA|March 23, 2026
Embracing Bayesian Methods in Clinical Trials: FDA's Long-Awaited Draft GuidanceJ Jack Lee, Frank E Harrell, Lisa M LaVange, et al.
Schizophrenia Bulletin|August 12, 2003
Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studiesSonia M Davis, Gary G Koch, C E Davis, et al.
Journal of Biopharmaceutical Statistics|June 22, 2013
Medical records-based postmarketing safety evaluation of rare events with uncertain statusHongyuan Cao, Lisa M LaVange, Joseph F Heyse, et al.
Journal of Biopharmaceutical Statistics|January 22, 2013
Medical records-based postmarketing safety evaluation of rare events with uncertain statusHongyuan Cao, Lisa M LaVange, Joseph F Heyse, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 23, 2011
Treatment intensity and characteristics of MRSA infection in CFMarianne S Muhlebach, Meredith Miller, Lisa M LaVange, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 8, 2024
Efficacy of infliximab, abatacept, and cenicriviroc for the treatment of adults hospitalized with COVID-19 pneumoniaDan-Yu Lin, Jianqiao Wang, Kevin J Anstrom, et al.
Chest|December 24, 2011
Questionnaires and pocket spirometers provide an alternative approach for COPD screening in the general populationSteven B Nelson, Lisa M LaVange, Yonghong Nie, et al.
American Journal of Respiratory and Critical Care Medicine|April 21, 2007
Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosisRobin R Deterding, Lisa M Lavange, Jean M Engels, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Statistics in Biopharmaceutical Research|June 30, 2021
Statistical Challenges in the Conduct and Management of Ongoing Clinical Trials During the COVID-19 PandemicToshimitsu Hamasaki, Frank Bretz, Freda Cooner, et al.
Journal of the American Statistical Association|May 3, 2014
Power Calculations for General Linear Multivariate Models Including Repeated Measures ApplicationsKeith E Muller, Lisa M Lavange, Sharon Landesman Ramey, et al.
JAMA|March 23, 2026
Embracing Bayesian Methods in Clinical Trials: FDA's Long-Awaited Draft GuidanceJ Jack Lee, Frank E Harrell, Lisa M LaVange, et al.
Schizophrenia Bulletin|August 12, 2003
Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studiesSonia M Davis, Gary G Koch, C E Davis, et al.
Journal of Biopharmaceutical Statistics|June 22, 2013
Medical records-based postmarketing safety evaluation of rare events with uncertain statusHongyuan Cao, Lisa M LaVange, Joseph F Heyse, et al.
Journal of Biopharmaceutical Statistics|January 22, 2013
Medical records-based postmarketing safety evaluation of rare events with uncertain statusHongyuan Cao, Lisa M LaVange, Joseph F Heyse, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 23, 2011
Treatment intensity and characteristics of MRSA infection in CFMarianne S Muhlebach, Meredith Miller, Lisa M LaVange, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 8, 2024
Efficacy of infliximab, abatacept, and cenicriviroc for the treatment of adults hospitalized with COVID-19 pneumoniaDan-Yu Lin, Jianqiao Wang, Kevin J Anstrom, et al.
Chest|December 24, 2011
Questionnaires and pocket spirometers provide an alternative approach for COPD screening in the general populationSteven B Nelson, Lisa M LaVange, Yonghong Nie, et al.
American Journal of Respiratory and Critical Care Medicine|April 21, 2007
Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosisRobin R Deterding, Lisa M Lavange, Jean M Engels, et al.
Pageof 4